As a company developing and manufacturing novel enzymes and marketing them to industrial customers, EUCODIS Bioscience offers its investors an attractive business model. Our white biotechnology business model significantly differs from that of "red" biotechnology, or the development of pharmaceuticals:

• Revenue base - incrementally growing
• Product development cycles are short
• High success rate in enzyme development
• Success of a candidate becomes apparent early in the development process
• Regulatory hurdles are low
• Enzyme development is much less capital-intensive

Enzymes bring high value to customers in a range of industries.